CA
NZ
UK
AU
IND
US
…
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Tvardi Therapeutics (NASDAQ: TVRD) is a small clinical-stage biotechnology company with limited public disclosures about its pipeline and operations. Its long-term growth would depend on successful clinical development, regulatory approvals, and licensing or commercialization of product candidates, which may benefit investors seeking early-stage oncology exposure.
Key risks include high clinical and regulatory execution risk, likely need for additional financing, limited operating history, and potential equity dilution.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -18.21M | -71.27M | -118.51M | -85.47M | -88.44M |
| Net income | -18.21M | -70.87M | -118.51M | -85.47M | -88.44M |
| Selling general administrative | 8.74M | 4.46M | 2.80M | 2.73M | - |
| Gross profit | -0.10M | 6.33M | 14.54M | 34.35M | 21.47M |
| Reconciled depreciation | 0.10M | 0.10M | 0.10M | 0.09M | - |
| Ebit | -18.21M | -62.79M | -117.91M | -85.47M | -88.44M |
| Ebitda | -18.12M | -62.60M | -117.65M | -83.80M | -86.89M |
| Depreciation and amortization | 0.10M | 0.19M | 0.26M | 1.67M | 1.55M |
| Operating income | -26.75M | -55.78M | -121.50M | -87.53M | -89.08M |
| Other operating expenses | 26.75M | 62.92M | 142.46M | 129.40M | 112.11M |
| Interest expense | - | 8.47M | 0.00M | 0.00M | - |
| Interest income | 1.38M | 0.75M | 1.32M | 0.65M | - |
| Net interest income | 1.38M | 0.75M | 1.32M | 0.65M | - |
| Income tax expense | - | -0.40M | - | - | - |
| Total revenue | 0.00M | 7.14M | 20.97M | 41.87M | 23.03M |
| Total operating expenses | 26.75M | 62.11M | 136.03M | 121.89M | 110.56M |
| Cost of revenue | 0.10M | 0.81M | 6.43M | 7.51M | 1.55M |
| Total other income expense net | 8.53M | -15.48M | 2.98M | 2.06M | 0.64M |
| Net income from continuing ops | -18.21M | -29.40M | -17.35M | -20.54M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 32.07M | 43.83M | 27.00M | 45.10M | 247.06M |
| Intangible assets | 0.32M | 0.39M | 0.45M | 0.51M | - |
| Other current assets | 0.73M | 0.53M | -0.78M | -4.08M | 2.52M |
| Total liab | 11.13M | 48.42M | 89.06M | 90.15M | 19.53M |
| Total stockholder equity | 20.95M | -4.59M | -62.06M | -45.05M | 227.52M |
| Other current liab | 7.71M | 2.54M | 1.58M | -0.13M | 10.24M |
| Common stock | 0.01M | 0.01M | 0.02M | 0.02M | 0.05M |
| Capital stock | 0.01M | 0.00M | 0.02M | 0.02M | - |
| Retained earnings | -110.45M | -755.61M | -62.84M | -45.49M | -480.76M |
| Cash | 20.73M | 37.90M | 22.92M | 21.49M | 13.45M |
| Total current liabilities | 11.04M | 3.97M | 3.28M | 4.28M | 17.62M |
| Net debt | -20.53M | 6.54M | -22.55M | -19.12M | -9.78M |
| Short term debt | 0.12M | - | 0.09M | 2.00M | 1.75M |
| Short long term debt total | 0.20M | 44.45M | 0.37M | 2.37M | 3.67M |
| Other stockholder equity | 131.38M | 751.01M | 0.76M | 0.45M | 708.59M |
| Total current assets | 31.54M | 43.83M | 26.16M | 44.11M | 173.29M |
| Short term investments | 10.08M | 0.00M | 48.98M | 22.25M | 153.58M |
| Net receivables | - | 4.50M | 4.02M | 4.45M | 1.15M |
| Long term debt | - | 30.26M | - | - | - |
| Inventory | - | 0.90M | - | - | 2.58M |
| Accounts payable | 3.22M | 1.43M | 1.61M | 2.41M | 5.62M |
| Accumulated other comprehensive income | 0.01M | - | -0.26M | -0.02M | -0.36M |
| Non currrent assets other | 0.02M | 0.02M | -1.48M | -11.33M | - |
| Non current assets total | 0.54M | 3.51M | 0.84M | 0.99M | 73.77M |
| Capital lease obligations | 0.20M | 0.30M | 0.37M | 0.45M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -10.08M | 0.00M | 22.47M | -22.00M | - |
| Total cashflows from investing activities | -10.08M | 48.74M | 43.46M | -22.00M | -4.75M |
| Net borrowings | 0.00M | 28.30M | - | - | - |
| Total cash from financing activities | 22.70M | -3.60M | 38.15M | 0.00M | 46.61M |
| Net income | -18.21M | -70.87M | -118.51M | -20.54M | -88.44M |
| Change in cash | -10.88M | -14.28M | -11.97M | -39.86M | -18.23M |
| Begin period cash flow | 31.61M | 52.18M | 64.15M | 61.35M | 31.68M |
| End period cash flow | 20.73M | 37.90M | 52.18M | 21.49M | 13.45M |
| Total cash from operating activities | -23.50M | -60.92M | -92.08M | -17.87M | -60.09M |
| Issuance of capital stock | 0.53M | 0.01M | 0.00M | 0.00M | - |
| Depreciation | 0.10M | 0.19M | 0.26M | 0.09M | 1.55M |
| Other cashflows from investing activities | - | - | 115.98M | - | - |
| Change to inventory | - | -1.04M | -0.44M | - | -2.58M |
| Change to account receivables | - | 2.02M | 0.44M | -3.30M | 0.91M |
| Other cashflows from financing activities | 22.17M | - | -36.47M | - | - |
| Capital expenditures | 0.00M | 1.05M | 2.38M | 0.05M | 0.04M |
| Change in working capital | 0.51M | -15.10M | 10.17M | 2.67M | 5.26M |
| Stock based compensation | 1.40M | 0.32M | 0.31M | 0.25M | - |
| Other non cash items | -7.29M | 24.86M | 16.01M | -0.32M | 21.54M |
| Free cash flow | -23.50M | -61.96M | -94.45M | -17.92M | -60.13M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| TVRD Tvardi Therapeutics, Inc. |
0.03 3.68% |
0.83 | - | - | 559.61 | 2.88 | 539.62 |
| NVO Novo Nordisk A/S |
-0.24 0.61% |
40.20 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 |
| VRTX Vertex Pharmaceuticals Inc |
-21.28 3.85% |
531.87 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 |
| REGN Regeneron Pharmaceuticals Inc |
12.10 1.26% |
973.36 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 |
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
3 Sugar Creek Center Boulevard, Sugar Land, TX, United States, 77478
713 489 8654
12
| Name | Title | Year Born |
|---|---|---|
| Dr. Imran Alibhai Ph.D. | CEO & Director | 1976 |
| Mr. Dan Conn J.D., M.B.A. | CFO & Corporate Secretary | 1968 |
| Dr. John Kauh M.D. | Chief Medical Officer | 1974 |
| Mr. David J. Tweardy M.D. | Co-Founder & Scientific Advisory Board Member | NA |
| Dr. Ronald A. DePinho M.D. | Co-Founder & Chairman of Scientific Advisory Board | 1955 |
| Dr. Michael T. Lewis Ph.D. | Co-Founder & Scientific Advisory Board Member | NA |
| Dr. Jeffrey Larson DABT, Ph.D. | Senior Vice President of R&D | 1962 |
| Mr. Stephen O'Brien CPA | VP of Finance & Corporate Controller | NA |
| Dr. Yixin Chen Ph.D. | Vice President of CMC | 1961 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.39%
Communication Services
+0.40%
Consumer Cyclical
-0.20%
Consumer Defensive
-0.56%
Energy
-0.45%
Financial Services
-0.09%
Financials
+0.11%
Healthcare
+0.40%
Industrials
+0.34%
Real Estate
-0.14%
Technology
+0.88%
Utilities
+0.11%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...